Business Update Positive

2026-05-27 18:26

Aurobindo Pharma Limited reported an excellent Q4 FY26 and strong financial year, achieving highest-ever revenues and EBITDA. For FY26, revenues reached ₹33,653 crores (▲6% YoY), and EBITDA ₹6,856 crores (▲4% YoY), with a healthy EBITDA margin of 20.4%. Net profit increased by 2% YoY to ₹921 crores for the quarter. The company expects FY27 EBITDA margins to progressively improve to north of 21%. Key growth drivers include: US business aiming for $2 billion revenue in the near term, European formulations targeting minimum double-digit growth in constant currency after achieving €1 billion in FY26. The Biosimilars business expects revenues from Unit-1 in 2028 and Unit-2 in 2031, targeting 7-8 products in Europe and growth markets and 2-3 in US by 2030, with gross margins of 65-75%. The CDMO unit also projects revenues from 2028. Pen-G and 6-APA businesses showed positive EBITDA contribution in Q4 FY26, with external sales initiated. India business is expected to grow double-digit.

Business Update Neutral

2026-05-27 16:04

Aurobindo Pharma Limited announced its officials will participate in a group meeting during the Investec US Pharma and Healthcare Bus Tour 7.0 on June 4, 2026, from 13:00 to 15:00 EDT in New Jersey, USA. The company stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Business Update Neutral

2026-05-27 16:01

Aurobindo Pharma Limited announced its participation in the BofA 2026 India Conference on June 2, 2026, from 9:00 AM to 6:00 PM IST in Mumbai. The company officials will engage in in-person and group meetings, and confirmed that no unpublished price sensitive information (UPSI) will be discussed.

Business Update Neutral

2026-05-25 18:28

Aurobindo Pharma Limited announced its participation in the Trinity India 2026 - 16th Annual Global Investor Conference, arranged by 360 ONE Capital. Company officials will attend in-person and group meetings in Mumbai on May 29, 2026, from 09:00 AM to 06:00 PM (IST). The company clarified that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Business Update Negative

2026-05-24 17:39

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited's Unit-I formulation manufacturing facility received an "Official Action Indicated" (OAI) classification from the US FDA. The inspection, conducted from February 16-27, 2026, initially concluded with 4 observations. The company stated there is no immediate impact on its financials or operations due to this action.

Business Update Positive

2026-05-22 12:35

Aurobindo Pharma Limited's wholly-owned step-down subsidiary, Agile Pharma BV, has incorporated a new wholly-owned subsidiary, Arrow Pharma Production SAS, in France on May 21, 2026. The new entity, with an authorized capital of 100,000 EUR, will focus on expanding the manufacturing of generic formulations in France.

Governance Neutral

2026-05-21 21:10

Aurobindo Pharma Limited announced the re-appointment of M/s. Ernst & Young LLP as its Internal Auditors for the period from June 2026 to May 2027. The re-appointment was approved by the Board of Directors at their meeting held on May 21, 2026.

Governance Negative

2026-05-21 21:05

CRITICAL RED FLAG DETECTED

Aurobindo Pharma announced the resignation of M/s. MRR & Associates as its Secretarial Auditor, effective May 22, 2026, due to health issues of its sole proprietor. Concurrently, the Board approved the appointment of M/s. RPR & Associates as the new Secretarial Auditor for a five-year term, commencing from FY 2026-27 to FY 2030-31, subject to shareholder approval at the ensuing Annual General Meeting.

Governance Neutral

2026-05-21 20:54

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced the resignation of M/s. MRR & Associates as Secretarial Auditor effective May 22, 2026, citing health issues of its sole proprietor. Concurrently, the Board approved the appointment of M/s. RPR & Associates as the new Secretarial Auditors for a five-year term commencing from FY 2026-27, subject to shareholder approval.

Financials Positive

2026-05-21 20:46

Consolidated Revenue from Operations was ₹8,853 Cr vs ₹8,382 Cr (▲5.6% YoY), EBITDA was ₹1,801 Cr vs ₹1,792 Cr (▲0.5% YoY), and Net Profit was ₹921 Cr vs ₹903 Cr (▲2.0% YoY). EBITDA Margin was 20.3% vs 21.4% (▼104 bps). The company received final approval for 9 ANDAs from the USFDA during the quarter. Strong growth was noted in European and Growth Markets businesses, offsetting a decline in US revenue.

Financials Neutral

2026-05-21 19:44

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹8,853.34 Cr vs ₹8,382.12 Cr (▲5.62% YoY), EBITDA ₹1,869.82 Cr vs ₹1,926.73 Cr (▼2.95% YoY), PAT ₹920.84 Cr vs ₹902.83 Cr (▲1.99% YoY). EBITDA Margin 21.12% vs 22.98% (▼186bps). The Board also approved the resignation of Secretarial Auditors M/s. MRR & Associates and appointed M/s. RPR & Associates as their replacement for a term of five years.

Governance Negative

2026-05-16 21:42

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced that on May 6, 2026, the Hon'ble High Court of Telangana dismissed a writ petition filed by its promoter/promoter group members. The petition challenged a SEBI communication from October 23, 2020, which directed them to deposit ₹6.53 crores plus interest into the Investor Protection and Education Fund for alleged insider trading profits. The company states there is no impact on its financials or operations.

Business Update Positive

2026-05-16 09:51

Aurobindo Pharma Limited's wholly-owned subsidiary, CuraTeQ Biologics Private Limited, received CDSCO Marketing Authorisation (Form CT 23) for Bevqolva®, a Bevacizumab biosimilar. This authorization permits the manufacture and marketing of Bevqolva® (100 mg/4mL and 400 mg/16 mL vial presentations) for metastatic carcinoma of the colon or rectum, to be produced at CuraTeQ's facility in Hyderabad.

Ownership Positive

2026-05-15 19:02

Aurobindo Pharma Limited announced the extinguishment of 5,423,728 fully paid-up equity shares on May 14, 2026, following a buyback through the tender offer route at ₹1,475 per share, totaling up to ₹800 crore. This reduces the company's total issued, subscribed, and fully paid-up share capital from 58,08,01,623 to 57,53,77,895 equity shares.

Business Update Neutral

2026-05-14 16:04

Aurobindo Pharma Limited announced an earnings call to be held on May 22, 2026, at 8:30 AM IST, to discuss its Audited Financial Results for the fourth quarter and year ended March 31, 2026 (Q4 FY26). An earnings presentation will be made available on the company's website post results announcement.

Business Update Positive

2026-05-06 09:14

Aurobindo Pharma announced that its Unit-VII, an oral solid dosage manufacturing unit, received an Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated" (VAI). This follows a US FDA inspection from January 28 to February 10, 2026, during which a 'Form 483' was issued with 9 observations. The FDA has concluded that this inspection is now closed, indicating no further regulatory action is required.

Governance Negative

2026-05-04 18:14

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced the resignation of Dr. Sanjay Chaturvedi as Chief Executive Officer of Apitoria Pharma Private Limited, its wholly-owned subsidiary. Dr. Chaturvedi's resignation is effective from the close of business hours on May 4, 2026, as he is moving on to a different opportunity.

Business Update Positive

2026-05-01 13:59

Aurobindo Pharma's wholly-owned subsidiary, CuraTeQ Biologics, has received Health Canada's Notice of Compliance (NOC) for Bevqolva™, its bevacizumab biosimilar. This authorization grants formal marketing rights in Canada for the product, used to treat various cancers, including colorectal and lung. Bevqolva™ had previously secured marketing authorization from the MHRA and launched commercially in the UK in 2025. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Routine Neutral

2026-04-30 17:12

New Filing detected. See link for details.

Routine Neutral

2026-04-21 16:04

New Filing detected. See link for details.

Routine Neutral

2026-04-17 18:40

New Filing detected. See link for details.

Business Update Positive

2026-04-17 10:41

Aurobindo Pharma announced on April 17, 2026, receiving USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The product, with an estimated market size of US$ 50.2 million, will be launched immediately.

Business Update Positive

2026-04-15 16:09

Aurobindo Pharma's subsidiary, TheraNym Biologics, signed an additional product schedule with Merck Sharpe & Dohme (MSD), expanding an existing CMO agreement. TheraNym will invest USD 150-175 million to build a new Drug Substance manufacturing facility (Unit 2) with 60 KL bioreactor capacity for biologicals.

Routine Neutral

2026-04-09 16:25

New Filing detected. See link for details.

Routine Neutral

2026-04-08 11:42

New Filing detected. See link for details.

Business Update Positive

2026-04-07 18:18

Aurobindo Pharma received USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for type-2 diabetes. The product has an estimated market size of US$ 514 million, and Aurobindo is eligible for 180 days of shared generic drug exclusivity.

Business Update Positive

2026-04-07 18:16

Aurobindo Pharma received USFDA final approval for Dapagliflozin Tablets (5 mg and 10 mg), a generic equivalent of Farxiga, for type-2 diabetes. The approved product has an estimated market size of US$10.2 billion and Aurobindo Pharma is eligible for 180 days of shared generic drug exclusivity.

Business Update Positive

2026-04-06 16:03

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive top-line results for its Phase 3 study of Omalizumab Biosimilar BP11. The study met all primary endpoints, showing high comparability, and regulatory filings with EMA and FDA are planned by the end of Q2 2026.

Ownership Positive

2026-04-06 09:00

Aurobindo Pharma's Board approved a share buyback of up to 54,23,728 equity shares (0.93% of total equity) at ₹1,475 per share, totaling up to ₹800 crores. The Record Date for determining eligible shareholders is April 17, 2026.

Business Update Positive

2026-04-06 08:33

Aurobindo Pharma's Board approved transferring its domestic branded generic pharmaceutical formulations business to wholly-owned subsidiary Auropharm Limited for ₹143.21 Cr. The strategic move aims to streamline and accelerate domestic business for faster growth and operational efficiency. The Business Transfer Agreement was executed on April 6, 2026.

Business Update Positive

2026-04-06 08:30

Aurobindo Pharma's Board approved a share buyback of up to 54.23 lakh shares (0.93% of paid-up capital) at ₹1,475 per share, totaling ₹800 crore. The Record Date for determining entitlement is April 17, 2026.

Business Update Neutral

2026-03-30 17:44

Aurobindo Pharma updated on acquiring 26% stake in Swarnaakshu Solar Power and a captive solar power purchase agreement. Completion, originally by March 31, 2026, is now expected by June 30, 2026, subject to state government approval for the captive solar power plant.

Governance Positive

2026-03-30 12:22

Aurobindo Pharma's postal ballot resulted in the approval of Dr. Punita Kumar Sinha's appointment as an Independent Director for 3 years (Feb 9, 2026 - Feb 8, 2029) with a 98.96% majority.

Business Update Positive

2026-03-25 16:58

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has entered into a marketing and distribution agreement with STADA Arzneimittel AG for two EMA-approved biosimilars in EU territories, including France and Germany. This strategic partnership aims to expand market reach and drive revenue growth.

Routine Neutral

2026-03-23 17:55

Aurobindo Pharma announced the closure of its trading window for designated persons from April 1, 2026, until 48 hours after the declaration of the Audited Financial Results for the financial year ending March 31, 2026. The Board Meeting date will be intimated later.

Business Update Positive

2026-03-20 10:01

Aurobindo Pharma's subsidiary, Apitoria Pharma, received a 'Voluntary Action Indicated' (VAI) classification from the US FDA for its Unit-V manufacturing facility, closing the inspection which initially resulted in 3 observations.

Business Update Negative

2026-03-17 16:27

CRITICAL RED FLAG DETECTED

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Limited's Unit-II, has received an 'Official Action Indicated' (OAI) classification from the US FDA following an inspection from Nov 3-14, 2025, which also resulted in a Form 483 with 9 observations. The company states it doesn't foresee any business impact.

Business Update Negative

2026-03-13 12:55

CRITICAL RED FLAG DETECTED

Aurobindo Pharma received an order on March 12, 2026, from the Principal Commissioner of Customs and Central Tax confirming a GST demand and penalty of Rs. 77.61 Cr each, related to excess IGST refunds and ITC issues. The company plans to appeal and states no material financial/operational impact.

Business Update Positive

2026-03-12 09:50

AUROBINDO PHARMA announced that the US FDA inspection of its subsidiary's Unit-IV (APL Healthcare Limited) from Dec 2025, which had 5 observations (Form 483), is now classified as 'Voluntary Action Indicated' (VAI) and closed.

Business Update Positive

2026-03-11 13:23

Aurobindo Pharma Limited announced that company officials will participate in an Analyst/Investor group plant visit on March 17, 2026, from 09:00 AM to 05:00 PM (IST) at Vizag & Kakinada. No unpublished price sensitive information is intended to be discussed.

Business Update Positive

2026-03-11 13:21

Aurobindo Pharma Limited officials will participate in an analyst/investor group plant visit on March 16, 2026, at Vizag & Kakinada. No unpublished price sensitive information is intended to be discussed during the interactions.

Business Update Neutral

2026-03-09 14:46

Aurobindo Pharma officials will participate in an investor meeting arranged by BofA on March 13, 2026, in Singapore. No unpublished price sensitive information is intended to be discussed.

Business Update Positive

2026-03-04 12:15

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Limited, announced the launch of Pomalidomide Capsules (1, 2, 3, 4 mg) in the US market. This generic equivalent of Pomalyst® Capsules addresses an estimated market size of approximately US$ 3.3 billion.

Business Update Neutral

2026-03-02 12:18

Aurobindo Pharma Limited will participate in the Goldman Sachs India Pharma Corporate Days investor meeting on March 06, 2026. The meeting will be virtual/online, and no unpublished price sensitive information is intended to be discussed.

Business Update Positive

2026-03-02 09:53

Aurobindo Pharma clarified that on Feb 27, 2026, its Non-Executive Director, P. Sarath Chandra Reddy, was acquitted and discharged from all charges by the CBI Special Judge in the alleged Delhi Liquor Policy case, removing a significant legal and reputational overhang.

Business Update Negative

2026-02-27 16:11

CRITICAL RED FLAG DETECTED

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, had its Unit-I manufacturing facility inspected by the US FDA from Feb 16-27, 2026. The inspection concluded with 4 observations. The company will respond within stipulated timelines and reports no financial or operational impact.

Business Update Positive

2026-02-26 11:49

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Limited, received USFDA approval for Everolimus Tablets (0.25 mg, 0.5 mg, 0.75 mg, 1 mg). The approved product has an estimated market size of US$ 78 million and is expected to launch in Q1FY27.

Business Update Positive

2026-02-24 16:28

Aurobindo Pharma Limited has incorporated a new wholly-owned subsidiary, Engenra Biologics Private Limited, on February 24, 2026. This pharmaceutical subsidiary, with an initial capital of ₹10 lakhs and 100% cash subscription, aims to expand the company's contract manufacturing and other pharmaceutical operations.

Governance Neutral

2026-02-24 14:59

Aurobindo Pharma Limited announced a postal ballot to approve the appointment of Dr. Punita Kumar Sinha as an Independent Director for three years (Feb 9, 2026 - Feb 8, 2029). E-voting is from Feb 27, 2026, to Mar 28, 2026, with results by Mar 30, 2026.

Business Update Negative

2026-02-19 15:14

CRITICAL RED FLAG DETECTED

Aurobindo Pharma received a demand from the GST Department for recovery of ₹169.83 Cr (including penalty) for alleged erroneous ITC refunds (Sept 2022-Dec 2022). The company will appeal the order, stating no material financial or operational impact.

Business Update Neutral

2026-02-18 13:34

Aurobindo Pharma clarified a news item regarding a US FDA inspection at its Unit-VII. The company stated the inspection was completed, they will respond within stipulated timelines, and confirmed no new material event requires disclosure as regulatory inspections are routine.

Financials Positive

2026-02-16 11:24

Consolidated Revenue ₹8,646Cr vs ₹7,976Cr (▲8.4% YoY), EBITDA ₹1,773Cr vs ₹1,627Cr (▲9% YoY), PAT ₹910Cr. EBITDA Margin 20.5%.

Business Update Positive

2026-02-13 18:35

Acrotech Biopharma Inc., a wholly owned stepdown subsidiary of Aurobindo Pharma Ltd, announced it has received US FDA approval for ADQUEY™ (difamilast 1%) Ointment for the topical treatment of mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older.

Business Update Negative

2026-02-10 22:09

CRITICAL RED FLAG DETECTED

Aurobindo Pharma's Unit-VII received a Form 483 with 9 procedural observations from the US FDA following an inspection from Jan 28 to Feb 10, 2026. The company will respond within stipulated timelines, stating no impact on its financials or operations.

Business Update Neutral

2026-02-10 07:03

Aurobindo Pharma Limited announced a revised investor/analyst presentation for its unaudited financial results for the third quarter and nine months period ended December 31, 2025, scheduled for February 10, 2026.

Business Update Positive

2026-02-09 20:05

Aurobindo Pharma's Board approved the merger of two wholly-owned subsidiaries, Auro Vaccines Private Limited into Curateq Biologics Private Limited, on February 9, 2026. The merger aims to reduce entities, optimize operational costs, and reduce regulatory compliances.

Business Update Positive

2026-02-09 20:01

Aurobindo Pharma's Board approved investing ₹66 crores to acquire up to 26% stake in Garuda Renewables Private Limited to secure renewable energy. This aims to achieve substantial power cost savings and enhance ESG profile by reducing carbon emissions.

Governance Positive

2026-02-09 19:56

Aurobindo Pharma appointed Dr.(Mrs.) Punita Kumar-Sinha as an Additional Director (Non-Executive Independent Director) for a 3-year term, effective February 9, 2026. Dr.(Mrs.) Deepali Pant Joshi ceased to be an Independent Director upon completion of her 2-year tenure, effective February 10, 2026.

Financials Positive

2026-02-09 19:49

Consolidated Revenue ₹8,646Cr vs ₹7,979Cr (▲8.4% YoY), EBITDA ₹1,773Cr vs ₹1,628Cr (▲9.0% YoY), PAT ₹910Cr vs ₹846Cr (▲7.6% YoY). EBITDA Margin 20.5% vs 20.4% (▲11bps).

Financials Neutral

2026-02-09 19:42

Aurobindo Pharma Limited has filed an Investor/Analysts Presentation for its unaudited financial results for the third quarter and nine months ended December 31, 2025, ahead of an analyst call on February 10, 2026.

Financials Positive

2026-02-09 19:34

Consolidated Revenue ₹8,645.9 Cr vs ₹7,978.5 Cr (▲8.4% YoY), EBITDA ₹1,403.8 Cr vs ₹1,199.8 Cr (▲17.0% YoY), PAT ₹909.8 Cr vs ₹845.6 Cr (▲7.6% YoY). EBITDA Margin 16.2% vs 15.0% (▲120bps). The quarter included an exceptional item of ₹65.3 Cr due to new Labour Codes.

Financials Positive

2026-02-09 19:20

Standalone Revenue ₹2,747.28Cr vs ₹2,916.63Cr (▼5.81% YoY), EBITDA ₹919.63Cr vs ₹767.41Cr (▲19.84% YoY), PAT ₹582.07Cr vs ₹472.05Cr (▲23.29% YoY). EBITDA Margin 33.47% vs 26.31% (▲716bps).

Business Update Neutral

2026-02-06 18:20

US FDA inspected Aurobindo Pharma's subsidiary Eugia Pharma's Unit-III from January 27 to February 06, 2026, concluding with 11 procedural observations. The company states there is no impact on its financials or operations.

Routine Neutral

2026-02-05 23:50

New Filing detected. See link for details.

Routine Neutral

2026-02-05 23:50

New Filing detected. See link for details.

AUROPHARMA

Aurobindo Pharma Limited

Filing History

Unlock Full History